Sim when you’re winning
World in Motion – Global equities blog

Sim when you’re winning

Simulation is reshaping industries. Take ANSYS1, a business which provides optimisation solutions to markets spanning aerospace, automotive, energy, materials and chemical processing – solutions which become deeply integrated into product design lifecycles. These enable engineers to emulate real world environments and better assess component quality and reliability in increasingly complex products. The result is faster speed-to-market, better decision making and risk mitigation. Having identified the potential of ANSYS early, our portfolios benefitted meaningfully from its rise to a $30 billion company today.2

There are signs that healthcare could provide another wave of simulation demand – especially in drug development:

Expected peak sales from therapies have been falling, by 54% between 2010 and 2019 among the top 12 biopharma companies, according to Deloitte (Figure 1).3

The costs of developing drugs are rising. Deloitte’s same study showed the average cost of bringing a drug to market increased by 67% during the 2010s.

Failure rates remain very high. Two-thirds of drug development programs never deliver an investigational new drug (IND) for clinical trials.

Regulatory requirements are unrelenting. The market for regulatory science and support alone is valued at more than $7 billion, compounding in the low-double digits.

Barriers for new entrants are falling. According to Charles River Laboratories4, biotech represented 70% of pipeline assets in 2019, up from 45% in 2014; while the estimated number of biopharma companies globally doubled to around 4,800 between 2011 and 2020.

Figure 1: higher costs and lower rewards in drug development

Source: Deloitte, 10 years on: Measuring the return from pharmaceutical innovation, 2020

The case for investment to boost drug development efficiency is therefore compelling; declining returns demand transformational shifts in R&D productivity. So, how can biosimulation help?

Computing power now not only enables companies to survive the deluge of biosimulation data available to them, but to make sense of it. Schrödinger5 is one business capitalising on this, with a platform which can evaluate billions of molecules a week, compared to 1,000 molecules a year using traditional laboratory-based methods. This is critical in lead optimisation.
A move along the drug development pathway to clinical trials brings our strategy’s second biosimulation play into view. Certara6 has developed core products which help to inform clinical trial design and mitigate unforeseen risks through population and organ modelling. Clinical stage work includes understanding how drugs affect the body, how the body processes and affects the drug, how different doses impact different population groups, and how drugs interact with one another. Biosimulation is proving increasingly helpful in these areas.

A third of all drugs approved by the FDA in 2019 utilised Simcyp, one of Certara’s core biosimulation solutions, up from 13% in 2014.7 Plus, to capitalise on the growing pipeline share of small- and mid-sized biotechs the company has established a comprehensive software, regulatory and market access service for smaller companies with ambitions in drug development which may lack resource or expertise. Between licensing and outsourcing services, we estimate around 60% of Certara’s revenue is generated through biosimulation, with prospects of attractive, durable growth from the prevailing industry trends.

Given the scalability of simulation business models, success means profitability. During 2006, ANSYS generated $264 million in revenue. Fast-forward to 2019 and that figure stood at over $1.5 billion (Figure 2). Gross margins are now touching 90%.8 Meanwhile, Schrödinger’s annualised software revenue is currently around $100 million. The company reports it is beginning to see step-ups in adoption from some of its largest customers, with 16 enrolled in annual contracts worth over $1 million – up from three in 2013.9 And while this business model is not all about the software given its drug development ambitions, gross margins in this division currently stand at 81%.10 With the biosimulation market’s value already exceeding $2 billion, backed by a sustainable, projected annual growth rate of 15%, the company’s roadmap to scale – and consequently, profitability – looks attractively paved.

Figure 2: ANSYS – a model for scalability

Source: Bloomberg, 2021

One of the most frequent lines we hear from healthcare management teams and analysts is that “changing healthcare is hard”. But the advancements of biosimulation may well prove to be one change companies can’t afford to ignore.

29 April 2021
Alex Beavis
Global Small Cap Analyst
Share article
Share on twitter
Share on linkedin
Share on email
April 2021
Share article
Share on twitter
Share on linkedin
Share on email

1 Mention of specific stocks is not a recommendation to buy
2 Past performance is not a guide to future returns
3 https://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/measuring-return-from-pharmaceutical-innovation.html, 2020
4 https://ir.criver.com/static-files/157c1622-808b-4c32-847d-23b8e933e860, 2019
5 Mention of specific stocks is not a recommendation to buy
6 Mention of specific stocks is not a recommendation to buy
7 https://ir.certara.com/static-files/7787d739-c148-49ce-a730-25f273fecd4b, 2020.
8 Bloomberg, 2021
9 https://ir.schrodinger.com/static-files/afed9256-e98b-403f-bb38-e88393f46336, 2021
10 https://ir.schrodinger.com/static-files/afed9256-e98b-403f-bb38-e88393f46336, 2021

Important Information

For use by Professional and/or Qualified Investors only (not to be used with or passed on to retail clients). This is an advertising document.

This document is intended for informational purposes only and should not be considered representative of any particular investment. This should not be considered an offer or solicitation to buy or sell any securities or other financial instruments, or to provide investment advice or services. Investing involves risk including the risk of loss of principal. Your capital is at risk. Market risk may affect a single issuer, sector of the economy, industry or the market as a whole. The value of investments is not guaranteed, and therefore an investor may not get back the amount invested. International investing involves certain risks and volatility due to potential political, economic or currency fluctuations and different financial and accounting standards. The securities included herein are for illustrative purposes only, subject to change and should not be construed as a recommendation to buy or sell. Securities discussed may or may not prove profitable. The views expressed are as of the date given, may change as market or other conditions change and may differ from views expressed by other Columbia Threadneedle Investments (Columbia Threadneedle) associates or affiliates. Actual investments or investment decisions made by Columbia Threadneedle and its affiliates, whether for its own account or on behalf of clients, may not necessarily reflect the views expressed. This information is not intended to provide investment advice and does not take into consideration individual investor circumstances. Investment decisions should always be made based on an investor’s specific financial needs, objectives, goals, time horizon and risk tolerance. Asset classes described may not be suitable for all investors. Past performance does not guarantee future results, and no forecast should be considered a guarantee either. Information and opinions provided by third parties have been obtained from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. This document and its contents have not been reviewed by any regulatory authority.

In Australia: Issued by Threadneedle Investments Singapore (Pte.) Limited [“TIS”], ARBN 600 027 414. TIS is exempt from the requirement to hold an Australian financial services licence under the Corporations Act and relies on Class Order 03/1102 in marketing and providing financial services to Australian wholesale clients as defined in Section 761G of the Corporations Act 2001. TIS is regulated in Singapore (Registration number: 201101559W) by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289), which differ from Australian laws.

In Singapore: Issued by Threadneedle Investments Singapore (Pte.) Limited, 3 Killiney Road, #07-07, Winsland House 1, Singapore 239519, which is regulated in Singapore by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289). Registration number: 201101559W. This document has not been reviewed by the Monetary Authority of Singapore.

In Hong Kong: Issued by Threadneedle Portfolio Services Hong Kong Limited 天利投資管理香港有限公司. Unit 3004, Two Exchange Square, 8 Connaught Place, Hong Kong, which is licensed by the Securities and Futures Commission (“SFC”) to conduct Type 1 regulated activities (CE:AQA779). Registered in Hong Kong under the ce (Chapter 622), No. 1173058.
In the UK: Issued by Threadneedle Asset Management Limited, registered in England and Wales, No. 573204. Registered Office: Cannon Place, 78 Cannon Street, London EC4N 6AG. Authorised and regulated in the UK by the Financial Conduct Authority.

In the EEA: Issued by Threadneedle Management Luxembourg S.A. Registered with the Registre de Commerce et des Sociétés (Luxembourg), Registered No. B 110242 44, rue de la Vallée, L-2661 Luxembourg, Grand Duchy of Luxembourg.

In the Middle East: This document is distributed by Columbia Threadneedle Investments (ME) Limited, which is regulated by the Dubai Financial Services Authority (DFSA).
For Distributors: This document is intended to provide distributors with information about Group products and services and is not for further distribution.
For Institutional Clients: The information in this document is not intended as financial advice and is only intended for persons with appropriate investment knowledge and who meet the regulatory criteria to be classified as a Professional Client or Market Counterparty and no other Person should act upon it.

In Switzerland: Threadneedle Asset Management Limited. Registered in England and Wales, Registered No. 573204, Cannon Place, 78 Cannon Street, London EC4N 6AG, United Kingdom. Authorised and regulated in the UK by the Financial Conduct Authority. Issued by Threadneedle Portfolio Services AG, Registered address: Claridenstrasse 41, 8002 Zurich, Switzerland.

Columbia Threadneedle Investments is the global brand name of the Columbia and Threadneedle group of companies.

Related Blog Posts

2 July 2021

David Dudding

Portfolio Manager, Global Equities

The power of compounding – a shaggy dog story

Read portfolio manager David Dudding on Junior Isas, Nestle and a cavapoo puppy.
Read time - 4 min
2 July 2021

Pauline Grange

Portfolio Manager, Global Equities

Fashion, Adidas and the circular economy

Adidas has been a core holding since the inception of the Threadneedle Global Sustainable Equity strategy. Its production and promotion of technical sports performance products contributes positively to our social theme of “Good Health and Wellbeing”.
Read time - 5 min
1 July 2021

Alex Lee

Portfolio Manager

Japan sets its sights on a software revolution

The use of software solutions by companies to improve competitiveness, efficiency and productivity, and reduce costs, is picking up pace – just in time, as a shortage of skilled workers continues to bite
Read time - 3 min

You may also like

Investment approach

Teamwork defines us and is fundamental to our investment approach, which is structured to facilitate the generation, assessment and implementation of good, strong investment ideas for our portfolios.

Funds and Prices

Columbia Threadneedle Investments has a comprehensive range of investment funds catering for a broad range of objectives.

Investment Strategies

We offer a broad range of actively managed investment strategies and solutions covering global, regional and domestic markets and asset classes.